Repare Therapeutics Inc
RPTX2.650USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
113.91MMarket Cap
LossP/E TTM
More Details of Repare Therapeutics Inc Company
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc Info
Ticker SymbolRPTX
Company nameRepare Therapeutics Inc
IPO dateJun 19, 2020
CEOForte (Steve)
Number of employees129
Security typeOrdinary Share
Fiscal year-endJun 19
Address7210 Frederick-Banting, Suite 100
CityST-LAURENT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeH4S 2A1
Phone18574127018
Websitehttps://www.reparerx.com/
Ticker SymbolRPTX
IPO dateJun 19, 2020
CEOForte (Steve)
Company Executives of Repare Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-4000.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-7500.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Switzerland
11.62M
0.00%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Other
71.82%
Shareholders
Shareholders
Proportion
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
Other
71.82%
Shareholder Types
Shareholders
Proportion
Hedge Fund
12.13%
Investment Advisor/Hedge Fund
11.03%
Investment Advisor
8.95%
Private Equity
7.51%
Individual Investor
0.31%
Venture Capital
0.31%
Research Firm
0.17%
Family Office
0.09%
Other
59.51%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
116
24.72M
57.35%
-9.60M
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blue Owl Capital Holdings LP
3.37M
7.82%
-71.16K
-2.07%
Nov 21, 2025
OrbiMed Advisors, LLC
3.20M
7.42%
-124.40K
-3.74%
Nov 21, 2025
Redmile Group, LLC
1.59M
3.68%
--
--
Sep 30, 2025
MPM Capital Inc.
1.12M
2.6%
--
--
Sep 30, 2025
MPM BioImpact LLC
819.92K
1.9%
--
--
Sep 30, 2025
Renaissance Technologies LLC
724.16K
1.68%
+201.30K
+38.50%
Sep 30, 2025
Citadel Advisors LLC
699.30K
1.62%
-238.19K
-25.41%
Sep 30, 2025
Rangeley Capital LLC
645.88K
1.5%
+290.58K
+81.79%
Sep 30, 2025
Acadian Asset Management LLC
568.30K
1.32%
-112.88K
-16.57%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
